Gilead Sciences Inc does not need to acquire for GILD stock to reverse course and trade higher. Brian & Liam take two angles on Gilead stock.
Gilead Sciences’ guidance was horrible, & GILD stock should be down 15%. There’s a good reason it only fell 5%, and why Gilead stock will recover.
GILD stock does not support Gilead Sciences’ HCV franchise, its $31 billion in cash, and significantly undervalues its HIV franchise.
GILD stock, AMGN stock, GOOGL stock, & IBM stock may not gain much from a reduction in the corporate tax rate, but not all are bad investments.
Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma
Acquisition predictions for 2017 that include VRX, GILD, AmEx, SPLK, & WFM being bought, and Takeda, Pfizer, Apple, IBM, and Kroger spending big.